AI Terminal
VALIRX PLC
Regulatory Filings • Jul 6, 2021
7998_rns_2021-07-06_fd846ed5-bca7-4c17-b9f7-6f42672bb78c.html
Regulatory Filings
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 2232E
ValiRx PLC
06 July 2021
6 July 2021
ValiRx PLC
("ValiRx", the "Company" or the "Group")
Patent Status Update
London, UK - ValiRx plc ("ValiRx", AIM:VAL), a clinical stage drug development company, is pleased to report that its patent portfolio continued to build in the first half of 2021.
2021 patent advances
| Project | Patent Family | Patent Granted | Date Granted | Impact |
| VAL201 | WO/2014/177868 Use of the peptide against metastases |
EP2991662 (European) |
June 2021 | Extends protection for the use of VAL201 into metastatic cancer, grant allowance announced January 2021 |
| VAL301 | WO/2013/064830 Use of the peptide against non-cancerous proliferative conditions |
IL232239 (Israel) |
June 2021 | Extends granted patent coverage into Israel for the use in the treatment of endometriosis, as well as other non-cancerous hormone-driven conditions |
| VAL401 | WO/2015/169971 | CN106456644 (China) |
June 2021 | The second Chinese patent granted for VAL401, extends the use into additional adenocarcinoma types |
The full patent portfolio for each project can be found on the project pages of the Company's website: https://www.valirx.com/our-pipeline
Dr Suzy Dilly, Chief Executive Officer commented: "I'm pleased to provide this periodic report of progress throughout our patent portfolio. Expanding geographical and scientific protection for these programmes provides a strong commercial background to promote to potential partners. This incremental increase in protection of our intellectual property estate provides foundation for company valuation growth."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.
Ends
For further information please contact:
| ValiRx plc | Tel: +44 (0) 2476 796496 www.valirx.com |
| Suzanne Dilly, CEO | [email protected] |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner / Ludovico Lazzaretti |
Tel: +44 (0) 20 7213 0880 |
| Peterhouse Capital Limited (Sole Broker) Duncan Vasey / Lucy Williams / Eran Zucker |
Tel: +44 (0) 20 7469 0930 |
| Optimum Strategic Communications Supriya Mathur/ Shabnam Bashir |
Tel: +44 (0) 20 8148 3040 [email protected] |
About ValiRx plc
ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.
With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
Integrating science and business
We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. We work closely with our selected collaborators and leverage the combined expertise required for science to advance.
Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCSSFFIIEFSESW